0001683168-18-002407.txt : 20180817 0001683168-18-002407.hdr.sgml : 20180817 20180817170031 ACCESSION NUMBER: 0001683168-18-002407 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180817 DATE AS OF CHANGE: 20180817 EFFECTIVENESS DATE: 20180817 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RXi Pharmaceuticals Corp CENTRAL INDEX KEY: 0001533040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-293158 FILM NUMBER: 181026367 BUSINESS ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 BUSINESS PHONE: (508) 767-3861 MAIL ADDRESS: STREET 1: 257 SIMARANO DRIVE STREET 2: SUITE 101 CITY: MARLBOROUGH STATE: MA ZIP: 01752 D/A 1 primary_doc.xml X0708 D/A LIVE 0001533040 RXi Pharmaceuticals Corp 257 SIMARANO DRIVE SUITE 101 MARLBOROUGH MA MASSACHUSETTS 01752 508-767-3861 DELAWARE None None Corporation true Geert Cauwenbergh c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Executive Officer Director Gerrit Dispersyn c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Executive Officer Robert Bitterman c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Keith Brownlie c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Paul Dorman c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Jonathan Freeman c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Curtis Lockshin c/o RXi Pharmaceuticals Corporation 257 Simarano Drive, Suite 101 Marlborough MA MASSACHUSETTS 01752 Director Pharmaceuticals Decline to Disclose 06b true 0001209191-17-049646 2017-08-08 true true false 0 15261000 1937904 13323096 45,000 shares issued to LPC 8/8/17 as initial consideration for put right granted to RXi under equity line; valued for purposes of this form at $5.80/share (closing stock price on 8/8/17 on Nasdaq Capital Market). false 1 0 0 0 false RXi Pharmaceuticals Corp /s/ Geert Cauwenbergh Geert Cauwenbergh President, CEO and acting CFO 2018-08-17